MYOK - MyoKardia: Addressing An Unmet Need In Hypertrophic Cardiomyopathy
MyoKardia (MYOK) is a slowly developing story with a two-year window of opportunity for investors before the company faces regulators. The company targets symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a disease where the heart muscle becomes abnormally thick, making it difficult for the heart to pump blood. Current standard of care is some medications but mostly invasive surgery, including open heart surgery; so there’s an unmet medical need for a drug therapy. We will review this company in the IOMachine, our four-factor test of investibility for specific drug/indication combos in biopharma.
MyoKardia “regained